
Reset all filters
01 2Tivdak
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 4
2022 Revenue in Millions : 0
Growth (%) : Acquired from Seagen
Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 131
2023 Revenue in Millions : 4
Growth (%) : 3,175